Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
Baxter
Boehringer Ingelheim
McKinsey

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022030

See Plans and Pricing

« Back to Dashboard

NDA 022030 describes TOVIAZ, which is a drug marketed by Pfizer and is included in one NDA. It is available from three suppliers. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TOVIAZ profile page.

The generic ingredient in TOVIAZ is fesoterodine fumarate. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fesoterodine fumarate profile page.
Summary for 022030
Tradename:TOVIAZ
Applicant:Pfizer
Ingredient:fesoterodine fumarate
Patents:8
Suppliers and Packaging for NDA: 022030
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030 NDA Pfizer Laboratories Div Pfizer Inc 0069-0242 0069-0242-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0242-30)
TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030 NDA Pfizer Laboratories Div Pfizer Inc 0069-0244 0069-0244-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0244-30)
Paragraph IV (Patent) Challenges for 022030
Tradename Dosage Ingredient NDA Submissiondate
TOVIAZ TABLET, EXTENDED RELEASE;ORAL fesoterodine fumarate 022030 2012-10-31

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength4MG
Approval Date:Oct 31, 2008TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Jul 3, 2022Product Flag?Substance Flag?YDelist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Patent:  Start TrialPatent Expiration:May 11, 2019Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Patent:  Start TrialPatent Expiration:Jun 7, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

Expired US Patents for NDA 022030

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-002 Oct 31, 2008   Start Trial   Start Trial
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008   Start Trial   Start Trial
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008   Start Trial   Start Trial
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-002 Oct 31, 2008   Start Trial   Start Trial
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-002 Oct 31, 2008   Start Trial   Start Trial
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Medtronic
Baxter
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.